NGC - Guideline Summary Sheet

NGC Guideline Summary Sheet

Overview

The Guideline Summary Sheet is the primary tool used to create the National Guideline Clearinghouse™ (NGC™) content. This tool contains all of the key attributes used to summarize each guideline for the purposes of creating the various standard view formats available at NGC Web site, including: the Brief Guideline Summary, the Complete Guideline Summary, the Guideline Comparison, and the Guideline Synthesis.

Outline

The following describes each attribute in the Guideline Summary Sheet:

Attribute	Description
Guideline Title	Identifies the complete title of the guideline.
Bibliographic Source(s)	Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline developer(s).
Number of References	Identifies the number of references cited in the guideline document.
Guideline Availability	Identifies information about the availability of the guideline. Where possible, information regarding electronic (including hypertext links to the full-text) and print copies is provided.
Availability of Companion Documents	Identifies the companion documents produced by the guideline developer that are relevant to the guideline. These companion documents are not necessarily available within NGC. For example, Quick Reference Guides and Technical Reports, both of which would be listed here, accompany guidelines produced by the Agency for Healthcare Research and Quality (AHRQ) (formerly the Agency for Health Care Policy and Research [AHCPR]).
Availability of Related Patient Resources	Identifies patient resources that are directly related (i.e., derived and/or prepared from the guideline by the guideline developer) to the guideline included in NGC. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.
Guideline Status/Update Information	Identifies whether the guideline is a revised or updated version of a previously issued document. Also identifies general information about the guideline developer's review and revision process and/or whether the guideline is currently under revision, when the next version is expected to be issued, etc.
Guideline Length	Identifies the total number of pages (collation) for published full-text guideline.
Issuing Organization(s)	Identifies the organization(s) responsible for issuing the guideline, when different from guideline developer
Guideline Developer(s)	Identifies the organization(s) responsible for the development of the guideline.
Guideline Developer Comment	If the guideline developer is a consortium or represents a group of organizations, this attribute identifies the individual organizations by name.
Guideline Endorser(s)	Identifies organization(s) that have endorsed the guideline, if they are identified in the text of the guideline document or explicitly by the guideline developer.
Adaptation	Identifies that the guideline has been adapted *from* another guideline and identifies the source document.
Organization Type	Classifies guideline developer(s) and endorser(s) by major designation or function. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Source(s) of Funding	Identifies source(s) of financial support for guideline development, as identified in the guideline text or by the guideline developer.
Funding Source ID	Identifies grant numbers associated with funding, as identified in the guideline text or by the guideline developer.
Guideline Committee	Identifies formal name, if any, of committee/subcommittee within the guideline developer organization(s) responsible for developing the guideline.
Composition of Group that Authored the Guideline	Describes the composition of the group/committee that authored the guideline, including professional degrees and affiliations, and lists the names of individual committee members, where given.
Date Released	Identifies the date the guideline was released to the public.
Guideline Category	Classifies the major focus of the guideline. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Clinical Specialty	Classifies the clinical specialties that might use the guideline professionally. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Disease/Condition(s)	Identifies the major areas of clinical medicine or health care addressed in the guideline. Values are expressed using the natural language expressions found in the text of the guideline.
Guideline Objective(s)	Describes the objectives of the guideline, as specified in the guideline text by the developers.
Method of Review of the Guideline Recommendations	Summarizes the methods used to review or validate the recommendations of the guideline. Validation is defined as "the results of any external review, comparison with guidelines from other groups or clinical testing of guideline use" (Hayward RSA, et al. More informative abstracts of articles describing clinical practice guidelines, Ann Intern Med 1993;118:731-737). Values are selected from the appropriate concepts in the NGC Classification Scheme.
Description of Method of Review of the Guideline Recommendations	Describes the method of review, presenting additional definition of the values stated for corresponding attribute "Method of Review of the Guideline Recommendations." Identifies pilot testing or trial periods of clinical implementation.
Implementation plan developed? (Yes/No)	Identifies if a plan for implementing the guideline recommendations was developed, enabling users to search for guidelines with implementation plans.
Description of Implementation Strategy	Describes specific strategies, aims, performance measures, or plans for implementing the guideline recommendations, if presented in the guideline or supplied by the guideline developer.
Intended Users	Classifies the groups intended to use the guideline. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Target Population	Describes the target population(s) addressed in the guideline. Identifies restrictions on guideline use such as within a managed care plan or geographic region.
Age of Target Population	Describes the age group(s) represented by the target population, enabling users to restrict their searches to a particular age group(s).
Sex of Target Population	Classifies the sex(es) represented by the target population, enabling users to restrict their searches to a particular gender.
Interventions and Practices Considered	Identifies the specific clinical interventions and practices considered in the guideline. Values are expressed using natural language expressions found in the text of the guideline.
Major Outcomes Considered	Describes the most important specific outcomes or performance measures considered in the guideline. Includes patient outcomes described in treatment guidelines and diagnostic test performance characteristics described in diagnosis or screening guidelines.
Cost Analysis	Describes any formal cost analysis performed, including the perspective.
Methods used to Collect the Evidence	Classifies the methods used to collect the evidence that was evaluated. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Description of Methods used to Collect the Evidence	Describes/summarizes the specific methods used to collect the evidence, as identified in the text of the guideline or by the guideline developer. Can include detailed search strategies, lists of journals scanned, keywords, database sources, etc.
Number of Source Documents	Identifies the number of source documents that were identified by the methods described above under "Description of Methods used to Collect the Evidence." The number of source documents is NOT the number of references.
Methods used to Assess the Quality and Strength of the Evidence	Classifies the methods used by the guideline developer to determine what relative importance to give the evidence they obtained. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Rating Scheme for the strength of the evidence	Presents rating scheme for strength of evidence, when given.
Methods used to Analyze the Evidence	Classifies the methods used by the guideline developer to evaluate the data in the evidence they obtained. Values are selected from the appropriate concepts in the NGC Classification Scheme.
Description of Methods used to Analyze the Evidence	Describes the methods used to analyze the evidence. Presents additional definition for the values presented under "Methods used to Analyze the Evidence" (for example, defines "systematic" or summarizes the details of the meta-analyses).
Qualifying statements	Presents qualifying statements or important caveats pertaining to the *major* recommendations of the guideline emphasized by the guideline developer. Identifies the area of uncertainty and presents a brief description of how the guideline developer addressed this uncertainty in developing the major recommendations of the guideline. Only caveats pertaining to the major recommendations are included. This attribute may also present information regarding uncertainty or controversies in the field identified by the guideline developer that prevents formulation of specific recommendations regarding important aspects within the guideline.
Major Recommendations	Identifies the major recommendations, copied verbatim from the guideline, if possible, or summarized by ECRI (with a notation "Summarized by NGC").
Clinical Algorithm(s)	Identifies which of the recommendations are expressed in the form of clinical algorithm(s).
Type of Evidence supporting Recommendations	Describes the type of evidence supporting the recommendations.
Potential Benefits	Describes the anticipated benefits associated with implementing the guideline's recommendations, as stated in the guideline text, to target populations or intended users.
Subgroup(s) of Patients most likely to Benefit	Describes the major subgroup(s) of patients within the Target Population most likely to benefit from the guideline recommendations, identified by the guideline developer.
Potential Harms	Describes the anticipated harms, potential risks or adverse consequences associated with the guideline's recommendations, as stated in the guideline text, to target populations or intended users.
Subgroup(s) of Patients most likely to Experience these Harms	Describes the major subgroup(s) of patients within the target population most likely to suffer harm/adverse consequences associated with the guideline recommendations, identified by the guideline developer.

NGC Guideline Summary Sheet

Overview

Outline

Search

About

Browse

Compare